Recombinant Human Parathyroid Hormone shortage — GR supply status & alternatives

Recombinant Human Parathyroid Hormone

—

In supply · Australia

Natpar

In supply · 🇦🇺 Australia · short in🇬🇷 GR🌐 IS

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Recombinant Human Parathyroid Hormone
Brand names	Natpar

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Verified timeline regulator events

🌐 2 July 2026

medium reported

🌐 1 June 2026

Shortage resolved

🌐 21 Apr 2026

Shortage resolved

🌐 4 Nov 2025

Shortage resolved

🇬🇷 14 July 2025

medium reported

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.